Saturday November 17, 2018

Effective Treatment to Protect Cancer Patients From Blood Clots

Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed.

0
//
For the
Blood cells, pixabay
Republish
Reprint

Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have shown.

People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) — either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.

The results from the clinical trial called “select-d” suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer.

“Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot,” said lead author Annie Young, Professor at the University of Warwick in Britain.

Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.

The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said. (IANS)
Representational image, pixabay

For the “select-d” trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE.

Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.

The results for secondary outcomes were mixed, the researcher said.

In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).

Also Read: Drug Used For Osteoporosis May Help in Reducing Heart Attack Risk

The reason for increased bleeding is not known. It may be because rivaroxaban is more ‘potent’, the paper published in the Journal of Clinical Oncology said. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

High Exposure to Radio Frequency Radiation Increase Risk of Cancer

Interestingly, the team found that rats exposed to whole body RFR lived longer than rats unexposed to any radiation

0
cancer
High exposure to radio frequency radiation linked to cancer. Pixabay

Exposure to high levels of radio frequency radiation (RFR) — used in 2G and 3G cell phones — can increase the risk of cancer tumours in the heart, brain and adrenal gland, researchers have warned.

The study, led by the US National Institutes of Health’s National Toxicology Programme (NTP), looked at the effects of exposing rodents to extremely high levels of radiofrequency throughout the entire body.

While high levels of RFR caused cancerous tumours in the heart (found very rarely in humans), brain and adrenal gland, of male rats, the findings on female rats were ambiguous.

“The exposures used in the studies cannot be compared directly to the exposure that humans experience when using a cell phone. In our studies, rats and mice received radio frequency radiation across their whole bodies,” John Bucher, researcher from the NTP, said in a statement.

“By contrast, people are mostly exposed in specific local tissues close to where they hold the phone,” Bucher added.

For the study, the team housed the animals in chambers specifically designed for the study.

Exposure to RFR began in the womb for rats and at 5 to 6 weeks old for mice, and continued for up to two years, or most of their natural lifetime.

Breast Cancer
Cancer ribbon. Pixabay

However, the RFR exposure was intermittent — 10 minutes on and 10 minutes off — totalling about nine hours each day.

In addition, the RFR levels ranged from 1.5-6 watts per kilogram in rats, and 2.5-10 watts per kilogram in mice.

“We believe that the link between radio frequency radiation and tumours in male rats is real,” Bucher noted.

Interestingly, the team found that rats exposed to whole body RFR lived longer than rats unexposed to any radiation.

“This may be explained by an observed decrease in chronic kidney problems that are often the cause of death in older rats,” the researchers noted.

Also Read- Actress Richa Chadha Speaks Upon Patriarchal Society

According to the US Food and Drug Administration (FDA), while animal studies contribute to discussions on the topic, “this study was not designed to test the safety of cell phone use in humans, so we cannot draw conclusions about the risks of cell phone use from it.”

Since the exposure levels and durations in the studies were greater than what people experience, “we agree that these findings should not be applied to human cell phone usage”, the FDA said on Thursday. (IANS)